Last reviewed · How we verify

NCT03814642

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants

Completed Phase 1 Last updated 21 October 2019
What this trial tests

Phase 1 trial testing Clopidogrel 75 mg in Healthy in 25 participants. Completed in 22 July 2019.

Timeline
21 January 2019
Primary endpoint
22 July 2019
22 July 2019

Quick facts

Lead sponsorHK inno.N Corporation
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment25
Start date21 January 2019
Primary completion22 July 2019
Estimated completion22 July 2019
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

HK inno.N Corporation — full company profile →

Who can join

Adults 19 to 50, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Clopidogrel 75 mg

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other HK inno.N Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03814642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing